Dalvance, Xydalba(dalbavancin)
Dalvance, Xydalba (dalbavancin) is an unknown pharmaceutical. Dalbavancin was first approved as Dalvance on 2014-05-23. It is used to treat bacterial infections, infectious skin diseases, staphylococcal infections, and streptococcal infections in the USA. It has been approved in Europe to treat bacterial skin diseases and soft tissue infections.
...
More
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
Dalvance
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| dalbavancin | New Drug Application | 2014-06-05 |
| dalvance | New Drug Application | 2025-01-13 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
DALBAVANCIN HYDROCHLORIDE, DALVANCE, ABBVIE | |||
| 2024-07-22 | NPP | ||
| 2024-05-23 | GAIN | ||
| 2019-05-23 | NCE | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Dalbavancin Hydrochloride, Dalvance, Abbvie | |||
| 6900175 | 2028-05-23 | U-3499 | |
HCPCS
Code | Description |
|---|---|
| J0875 | Injection, dalbavancin, 5 mg |
Clinical
Clinical Trials
3757 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 107 | 5 | 3 | 3 | 28 | 142 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 38 | 48 | 16 | 2 | 30 | 119 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 14 | 11 | 4 | 17 | 42 | 85 |
| Syndrome | D013577 | — | — | 8 | 26 | 7 | 5 | 37 | 78 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 7 | 9 | 7 | 2 | 45 | 70 |
| Leukemia | D007938 | — | C95 | 35 | 31 | 7 | 1 | 4 | 65 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 11 | 9 | 7 | 14 | 27 | 64 |
| Stroke | D020521 | EFO_0000712 | I63.9 | 3 | 7 | 8 | 2 | 40 | 58 |
| Lymphoma | D008223 | — | C85.9 | 33 | 28 | 5 | 2 | 1 | 56 |
| Infections | D007239 | EFO_0000544 | — | 10 | 12 | 15 | 9 | 13 | 53 |
Show 315 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 126 | 64 | 9 | — | 30 | 191 |
| Non-small-cell lung carcinoma | D002289 | — | — | 37 | 44 | 8 | — | 4 | 77 |
| Carcinoma | D002277 | — | C80.0 | 31 | 31 | 10 | — | 8 | 68 |
| Lung neoplasms | D008175 | — | C34.90 | 26 | 30 | 4 | — | 9 | 59 |
| Colorectal neoplasms | D015179 | — | — | 19 | 25 | 9 | — | 16 | 58 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 20 | 24 | 6 | — | 4 | 44 |
| Myeloid leukemia | D007951 | — | C92 | 18 | 23 | 6 | — | 2 | 41 |
| Melanoma | D008545 | — | — | 23 | 20 | 1 | — | 4 | 39 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 17 | 15 | 6 | — | 4 | 37 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 14 | 15 | 6 | — | 3 | 32 |
Show 277 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 12 | 14 | — | — | 2 | 24 |
| Head and neck neoplasms | D006258 | — | — | 9 | 10 | — | — | 5 | 22 |
| Glioblastoma | D005909 | EFO_0000515 | — | 7 | 11 | — | — | 1 | 17 |
| Spinal cord injuries | D013119 | EFO_1001919 | — | 2 | 3 | — | — | 13 | 16 |
| Weight loss | D015431 | — | — | — | 1 | — | — | 14 | 15 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 7 | 7 | — | — | 2 | 14 |
| Small cell lung carcinoma | D055752 | — | — | 7 | 8 | — | — | 2 | 12 |
| Emergencies | D004630 | — | — | — | 1 | — | — | 11 | 12 |
| Pruritus | D011537 | — | L29 | — | 1 | — | — | 10 | 11 |
| Body weight | D001835 | EFO_0004338 | — | — | 1 | — | — | 10 | 11 |
Show 280 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | 4 | — | — | — | 5 | 9 |
| Urinary incontinence | D014549 | — | R32 | 1 | — | — | — | 8 | 9 |
| Psychological burnout | D000077062 | — | Z73.0 | 1 | — | — | — | 8 | 9 |
| Pharmacokinetics | D010599 | — | — | 7 | — | — | — | — | 7 |
| Pulmonary arterial hypertension | D000081029 | — | — | 3 | — | — | — | 3 | 6 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | 1 | — | — | — | 5 | 6 |
| Gastroesophageal reflux | D005764 | EFO_0003948 | K21 | 1 | — | — | — | 5 | 6 |
| Neuroblastoma | D009447 | EFO_0000621 | — | 3 | — | — | — | 2 | 5 |
| Pancreatic ductal carcinoma | D021441 | — | — | 4 | — | — | — | 1 | 5 |
| Professional burnout | D002055 | — | — | 1 | — | — | — | 3 | 4 |
Show 121 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Trigger finger disorder | D052582 | — | M65.3 | — | — | — | — | 24 | 24 |
| Anxiety | D001007 | EFO_0005230 | F41.1 | — | — | — | — | 21 | 21 |
| Paralysis | D010243 | — | — | — | — | — | — | 9 | 9 |
| Cerebral palsy | D002547 | — | G80 | — | — | — | — | 8 | 8 |
| Sleep | D012890 | GO_0030431 | — | — | — | — | — | 8 | 8 |
| Myopia | D009216 | EFO_0003927 | H52.1 | — | — | — | — | 8 | 8 |
| Gingival recession | D005889 | — | K06.0 | — | — | — | — | 8 | 8 |
| Autism spectrum disorder | D000067877 | — | F84.0 | — | — | — | — | 7 | 7 |
| Dental implants | D015921 | — | — | — | — | — | — | 7 | 7 |
| Prediabetic state | D011236 | EFO_1001121 | R73.03 | — | — | — | — | 6 | 6 |
Show 586 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Dalbavancin |
| INN | dalbavancin |
| Description | Dalbavancin is a semisynthetic glycopeptide used for the treatment of acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms including MRSA. It has a role as an antibacterial drug and an antimicrobial agent. It is a carbohydrate acid derivative, a monosaccharide derivative, a glycopeptide and a semisynthetic derivative. ... More |
| Classification | Small molecule |
| Drug class | vancomycin-related compounds |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN[C@H]1C(=O)N[C@@H]2Cc3ccc(cc3)Oc3cc4cc(c3O[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3NC(=O)CCCCCCCCC(C)C)Oc3ccc(cc3Cl)[C@@H](O)[C@@H]3NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@@H](NC2=O)c2cc(cc(O)c2Cl)Oc2cc1ccc2O)c1ccc(O)c(c1)-c1c(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]2O)cc(O)cc1[C@@H](C(=O)NCCCN(C)C)NC3=O |
Identifiers
| PDB | — |
| CAS-ID | 171500-79-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3301669 |
| ChEBI ID | 82721 |
| PubChem CID | 16134627 |
| DrugBank | DB06219 |
| UNII ID | 808UI9MS5K (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Dalvance – Allergan
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Dalvance – Warner Chilcott
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7,919 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,011 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use